Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
It's also the moment it becomes vulnerable to a host of environmental factors: temperature, bacteria, oxidation, and physical agitation
Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
Membership in the LifeMD weight loss program gives you access to expert clinicians, weight loss coaching, lab work if necessary, and continuing care as you navigate weight loss with GLP-1s, with both injectable and oral options available
MASH Treatment Survodutide FDA Breakthrough Therapy Designation for MASH, Phase 3 LIVERAGE trials specifically designed for MASH, and Phase 2 data showing 62% MASH resolution at 4.8 mg dose
